TABLE 2.

A summary of features in the original dataset.

Items	Features
General patient information (four features)	Gender, age, body weight (abbreviation: BW), height
Substance abuse (three features)	Smoking history, drinking history, history of other substance abuse
Diagnosis and disorder history (three features)	Diagnosis of schizophrenia, diagnosis of bipolar affective disorder, allergic history
Blood types (two features)	ABO blood type, Rh blood type
Phenotypes, genotypes, and gene polymorphisms (13 features)	MTHFR (C677T) polymorphism, MTHFR phenotype, HLA-B*1502 genotype, CYP2C19 genotype, CYP2C19 phenotype, CYP2D6 genotype, CYP2D6 phenotype, CYP2D6 (G4180C) polymorphism, CYP2D6 (G2988A) polymorphism, CYP2D6 (C2850T) polymorphism, CYP2D6 (G1846A) polymorphism, CYP2D6 (C100T) polymorphism, ApoE genotype
Dosage regimens (three features)	Daily dose of OLZ [abbreviation: daily dose (OLZ)], dosage regimen of OLZ, daily dose frequency of OLZ
Combined drugs (280 features)	Valproic acid, risperidone, rifampicin, warfarin, clozapine, sertraline, fluvoxamine, perphenazine, carbamazepine, fluoxetine, etc.
Results of TDM measurements of other medications (24 features)	Concentrations of valproic acid [abbreviation: C (Valproic acid)], sertraline, fluoxetine, fluvoxamine, risperidone, oxcarbazepine, venlafaxine, clozapine, lamotrigine, perphenazine, aripiprazole, etc.
Information relating to biochemical analyses (140 features)	Time of TDM blood sampling after first administration of OLZ (abbreviation: time of blood sampling after first administration), alanine transaminase (abbreviation: ALT), serum potassium (abbreviation: K), serum sodium (abbreviation: Na), absolute monocyte count (abbreviation: MONO#), white blood cell count (abbreviation: WBC), red blood cell count (abbreviation: RBC), serum creatinine (abbreviation: Cr), uric acid (abbreviation: UA), creatine kinase (abbreviation: CK), C-reactive protein (abbreviation: CRP), total cholesterol (abbreviation: TC), etc.